1. Home
  2. HFBL vs LUNG Comparison

HFBL vs LUNG Comparison

Compare HFBL & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Home Federal Bancorp Inc. of Louisiana

HFBL

Home Federal Bancorp Inc. of Louisiana

HOLD

Current Price

$19.00

Market Cap

60.2M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$1.57

Market Cap

57.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HFBL
LUNG
Founded
1924
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.2M
57.9M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
HFBL
LUNG
Price
$19.00
$1.57
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
2.6K
547.1K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
2.83%
N/A
EPS Growth
7.69
7.64
EPS
1.55
N/A
Revenue
$1,303,000.00
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
$12.32
N/A
Revenue Growth
17.49
8.01
52 Week Low
$12.32
$1.13
52 Week High
$20.30
$3.88

Technical Indicators

Market Signals
Indicator
HFBL
LUNG
Relative Strength Index (RSI) 48.65 67.19
Support Level $18.02 $1.51
Resistance Level $19.26 $1.64
Average True Range (ATR) 0.36 0.09
MACD -0.12 0.04
Stochastic Oscillator 44.74 85.78

Price Performance

Historical Comparison
HFBL
LUNG

About HFBL Home Federal Bancorp Inc. of Louisiana

Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: